

GNE.2630P1C17

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ashkenazi et al. ) Group Art Unit: Unknown  
App. No. : 09/978,403 )  
Filed : October 16, 2001 )  
For : SECRETED AND )  
TRANSMEMBRANE )  
POLYPEPTIDES AND )  
NUCLEIC ACIDS ENCODING )  
THE SAME )  
Examiner : Unknown )

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office  
PO Box 2327  
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing 1 reference that is also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: February 14, 2002

By: Ginger R. Dreger

Ginger R. Dreger  
Registration No. 33,055  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
GNE 2630P1C17APPLICATION NO  
09/978,403INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
Ashkenazi et alFILING DATE  
October 16, 2001GROUP  
Unknown

(USE SEVERAL SHEETS IF NECESSARY)

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1.	Gold, <u>Mol. Neurobiol.</u> 15:285-306 (1997)

W:\DOCS\BGY\BGY-1986.DOC  
021402

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	